1-2 February 2020
Using our AI tools and biomedical knowledge graph we identified baricitinib as a potential treatment to inhibit viral infection.
4 February 2020
Our research was published in The Lancet and we signed the Wellcome Trust pledge to share our research in response to the emerging global health crisis
28 February 2020
We published a second paper which indicated that baricitinib reduces endocytosis and the body’s hyperinflammatory response to the virus, thus potentially reducing patient mortality.
10 April 2020
Eli Lilly (who owns baricitinib) announces that baricitinib will enter a randomised-control trial with the US National Institute of Allergy and Infectious Diseases (NIAID).
15 June 2020
Eli Lilly announced that they will commence an additional phase 3 clinical trial to evaluate the efficacy and safety of baricitinib to treat COVID-19.
26 June 2020
Further experimental data supporting our AI-derived hypothesis and early results from clinical testing were published in the European Molecular Biology Organization Molecular Medicine Journal. This research was conducted in partnership with Eli Lilly.
14 September 2020
Positive data released from the NIAID’s randomised-control trial showed that baricitinib in combination with remdesivir reduces the recovery time in hospitalised patients with COVID-19, validating our AI-derived hypothesis.